Immunology Collaboration and Licensing Deals 2016-2024


Immunology Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2024

Publication date
April 2024
Number of pages
Product type
Research report
Report edition

Immunology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the immunology deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of immunology deals from 2016 to 2024.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of immunology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in immunology dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the immunology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in immunology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of immunology deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of immunology deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in immunology deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


Key benefits

Immunology Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse immunology collaboration and licensing deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time


Report scope

Immunology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of immunology trends and structure of deals entered into by leading biopharma companies worldwide.

Immunology Collaboration and Licensing Deals includes:

  • Trends in immunology dealmaking in the biopharma industry
  • Overview of collaboration and licensing deal structure
  • Directory of immunology deal records covering pharmaceutical and biotechnology
  • The leading immunology deals by value
  • Most active immunology licensing dealmakers

In Immunology Collaboration and Licensing Deals, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.

Immunology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Immunology Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse immunology collaboration and licensing deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in immunology dealmaking


2.1. Introduction

2.2. Immunology partnering over the years     

2.3. Immunology partnering by deal type

2.4. Immunology partnering by industry sector

2.5. Immunology partnering by stage of development

2.6. Immunology partnering by technology type

2.7. Immunology partnering by therapeutic indication


Chapter 3 – Financial deal terms for immunology partnering


3.1. Introduction

3.2. Disclosed financials terms for immunology partnering

3.3. Immunology partnering headline values

3.4. Immunology deal upfront payments

3.5. Immunology deal milestone payments

3.6. Immunology royalty rates


Chapter 4 – Leading immunology deals and dealmakers


4.1. Introduction

4.2. Most active in immunology partnering

4.3. List of most active dealmakers in immunology    

4.4. Top immunology deals by value


Chapter 5 – Immunology contract document directory


5.1. Introduction

5.2. Immunology partnering deals where contract document available


Chapter 6 – Immunology dealmaking by therapeutic target


6.1. Introduction

6.2. Deals by immunology therapeutic target


Deal directory


Deal directory – Immunology deals by company A-Z 2016 to 2024

Deal directory – Immunology deals by technology type 2016 to 2024


Deal type definitions


About Biopharma Research Ltd


Current Partnering

Current Agreements

Recent report titles from Current Partnering


Table of figures


Figure 1: Immunology partnering since 2016

Figure 2: Immunology partnering by deal type since 2016

Figure 3: Immunology partnering by industry sector since 2016

Figure 4: Immunology partnering by stage of development since 2016

Figure 5: Immunology partnering by technology type since 2016

Figure 6: Immunology partnering by indication since 2016

Figure 7: Immunology deals with a headline value

Figure 8: Immunology deals with upfront payment values

Figure 9: Immunology deals with milestone payment

Figure 10: Immunology deals with royalty rates

Figure 11: Active immunology dealmaking activity since 2016

Figure 12: Top immunology deals by value since 2016

Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by Evalon.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

2seventy bio, 4C Biomed, 4P-Pharma, 4SC, 7 Hills Pharma, 9 Meters Biopharma, 23andMe, A*STAR Agency for Science, Technology and Research, A*STAR Genome Institute of Singapore, AB2 Bio, AB Biosciences, Abbvie, AbCellera Biologics, Abcuro, Abdul Latif Jameel Health, Abingworth Management, ABL Bio, Ablynx, Abpro, Abreos Biosciences, AbSci, ABVC BioPharma, Abveris, Abzena, Accutar Biotechnology, AcedrA BioPharmaceuticals, Acelyrin, AC Immune, Actelion, Acucela, AcuCort, Acuitas Therapeutics, AdAlta, Adamis Pharmaceuticals, Adaptate Biotherapeutics, Adaptive Biotechnologies, Adicet Bio, Adimune, Aditx Therapeutics, Aduro BioTech, Advanz Pharma, Advaxis, AESOP Technology, Aevi Genomic Medicine, Aevitas Therapeutics, Affibody, AffyXell Therapeutics, AGC Biologics, Agenus Bio, AgomAb Therapeutics, AHN Autoimmunity Institute, AiCuris, Aimmune Therapeutics, AI Proteins, Ajinomoto, Akoya Biosciences, Akrevia Therapeutics, Akriveia Therapeutics, Alder Biopharmaceuticals, Aldeyra Therapeutics, Alexion Pharmaceuticals, ALK-Abello, Allakos, Allegheny General Hospital, Allen Institute for Immunology, AllerGenis, Alliance for Lupus Research, Allogene Therapeutics, Alloksys Life Sciences, Alloy Therapeutics, Almirall, Alpha Cancer Technologies, Alpine Immune Sciences, Altamira Pharma, AltaVoice, Alvotech, Alyatec, Amagma Therapeutics, Ambiopharm, Amegabiotech, American Type Culture Collection (ATCC), Amgen, AMPEL BioSolutions, Amphista Therapeutics, Ampio Pharmaceuticals, Amunix, Amytrx Therapeutics, AnaMar, AnaptysBio, Anergis, Angany, Anima Biotech, Annapurna Therapeutics, Anokion, Antibe Therapeutics, Antisoma Therapeutics, Apellis Pharmaceuticals, Apocell, Apollo Therapeutics, Applied BioMath, AprilBio, Aptahem, Aptar Pharma, Aptorum Group, Aqemia, Aqilion, Aratana Therapeutics, Arbele, Arbor Biotechnologies, Arbutus, Archer Daniels Midland Company, ArcherDX, Arcus Biosciences, Arcutis Biotherapeutics, Arena Pharmaceuticals, argenx, Argonne National Laboratory, Ariceum Therapeutics, Aristea Therapeutics, Array Biopharma, Arrien Pharmaceuticals, ARS Pharmaceuticals, Artelo Biosciences, Artisan Bio, Artizan Biosciences, Asahi Kasei, AskAt, Aslan Pharma, Astellas Pharma, Astellas Pharma US, AstraZeneca, Atara Biotherapeutics, Atomwise, Atreca, Aurigene Discovery Technologies, Aurinia Pharmaceuticals, Australian Research Council, Autolus, Avacta, Avactis Biosciences, Avalere Health, Avalon GloboCare, Avalo Therapeutics, Avectas, Avicanna, Aviceda Therapeutics, Avidity Biosciences, Avillion, Avivo Biomedical, Avrobio, Axcelead Drug Discovery Partners, Axela, Azenta Life Sciences, Bausch & Lomb, Baxalta, Bayer, Bayer Animal Health, B Braun, BCD Bioscience, Beacon Discovery, Beactica, Becton Dickinson, BeiGene, Beijing InnoCare Pharma, Beijing Tianshi Tongda Pharmaceuticals Technology, Belharra Therapeutics, Benaroya Research Institute, BenevolentAI, Bennu Pharmaceuticals, Berg, Berkeley Lights, Be The Match BioTherapies, Beth Israel Deaconess Medical Center, Bicycle Therapeutics, Bill and Melinda Gates Foundation, Bio-Cancer Treatment International, Bio-Me, Bio-Path, Bio-Techne, BioAge Labs, BioBright, Biocartis, Biocon, BioCopy, BioCryst Pharmaceuticals, Biocytogen, BioDuro, Biogen, Biohaven Pharmaceuticals, BioKey, Biolojic Design, BioMed X Innovation Center, Biomunex Pharmaceuticals, BioNova Pharmaceuticals, Bioqube Ventures, BioRap Technologies, BiosanaPharma, BioSenic, BioSense Global, Biosortia Pharmaceuticals, Biotest, BioVectra, Blacksmith Medicines, Blau Pharma, Bloom Science, BlueRock Therapeutics, BlueWillow Biologics, Boehringer Ingelheim, Boston Pharmaceuticals, Bpifrance, Brain Canada, Brickell Biotech, Bridge Biotherapeutics, Brigham and Women's Hospital, Bright Peak Therapeutics, Brii Biosciences, Bristol-Myers Squibb, Broad Institute, Bruno Farmaceutici, Bryn Pharma, BullFrog AI, C4X Discovery, Cabaletta Bio, Caelum Biosciences, California Institute for Regenerative Medicine, Calliditas Therapeutics, Calypso Biotech, Cambridge Enterprise, Camurus, Canadian Council, CANbridge Pharmaceuticals, Cancer Genetics, Cancer Research Institute, Cantargia, Carbiotix, CareFirst BlueCross BlueShield, Carna BioSciences, Carnegie Mellon University, Casebia Therapeutics, CASI Pharmaceuticals, Cassie + Friends, Catalyst Pharmaceuticals, CB2 Therapeutics, Cedars-Sinai Medical Center, Celgene, Cellectis, Cellgen Diagnostics, Cell Mogrify, CellSight Technologies, Centessa Pharmaceuticals, Centogene, Central Institute for Experimental Animals, Centre for Commercialization of Regenerative Medicine (CCRM), Centre Leon Berard, Centurion, Century Therapeutics, Cerecor, Changchun High & New Technology Industries, Charite-Universitatsmedizin, Charite Universitatsmedizin Berlin, Charles River Laboratories, Checkpoint Therapeutics, Chi-Med, Children's Hospital Boston, China Medical System, ChromaDex, Chromocell, Chugai Pharmaceutical, Chugai Pharma Marketing, Cincinnati Children’s Hospital Medical Center, Circuit Clinical, City of Hope, ClinConnect, Clinical Ink, CMS Medical, Coeptis Therapeutics, Coherus Biosciences, CoImmune, Columbia University, Commense, Conduit Pharmaceuticals, ConsortiaTX, Corbin Therapeutics, Corbus Pharmaceuticals, Corden Pharma, Cornell University, Corrona, COUR Pharmaceutical, Coya Therapeutics, Crescendo Biologics, CRISPR Therapeutics, Cristal Therapeutics, Cromos Pharma, Crown Bioscience, Cryostem, CSL Behring, CSL Plasma, CSPC Pharmaceutical Group, Cue Biopharma, Cugene, Cullinan Oncology, Curable, Curadev Pharma, Curetis, Cyclacel Pharmaceuticals, Cyclenium Pharma, Cygnus, Cynata Therapeutics, Cyntar Ventures, Cyrus Biotechnology, CytoAgents, Cytobank, Cytocom, CytoLynx Therapeutics, CytomX Therapeutics, CytoReason, CytoSorbents, CYTOVIA Therapeutics, Daewoong Pharmaceutical, Daiichi Sankyo, Dalhousie University, Dana-Farber Cancer Institute, Danuo Science Group, DAS Therapeutics, DBV Technologies, Decode Health, Defense Advanced Research Projects Agency, DEKA Research and Development, Delta 4, Denali Therapeutics, Department of Defense, Dermira, Devonian Health Group, DiaCarta, Dianomi Therapeutics, DKSH, DNAnexus, DNAtrix, DNX Biopharmaceuticals, Dong-A ST, Dragonfly Therapeutics, Dualogics, Duke University, DyDo Pharma, DynamiCure Biotechnology, Edesa Biotech, EdiGene, Egle Therapeutics, Eilean Therapeutics, Eisai, Eisai Inc, Eli Lilly, Elpis Biomed, ElsaLys Biotech, Emergex Vaccines, Enable Biosciences, Enamine, Enesi Pharma, Enosi Therapeutics, Ensemble Therapeutics, Entera Bio, Enterome Bioscience, Entos Pharmaceuticals, Enzychem Lifesciences, EpiAxis Therapeutics, EpimAb Biotherapeutics, Epivax, EQRx, Equillium, Erasmus University Medical Center, Erytech Pharma, Escient Pharmaceuticals, Essex Bio-Technology, Eton Pharmaceuticals, Eurofins Discovery, Eurofins Scientific, European Union, Eutilex, Evax, Evelo Biosciences, Everest Medicines, Evidation Health, Evommune, EVOQ Therapeutics, Evotec, Exagen Diagnostics, Excelra, Expert Systems Inc, ExScientia, F-Star, F-Star Therapeutics, FairJourney Biologics, Federal Ministry of Health (Germany), Feinstein Institute for Medical Research, Feldan Therapeutics, Ferring Pharmaceuticals, Fibrocell Science, Fibrogen, Five Prime Therapeutics, Fluo Labs, Folia Biotech, Food Allergy Research & Education, Food and Drug Administration (FDA), Forge Biologics, Fortress Biotech, Foundation Medicine, Foundery Innovations, Fred Hutchinson Cancer Research Center, French National Institute for Agricultural Research, FSD Pharma, Fujifilm, FUJIFILM Cellular Dynamics, Fuji Pharma, Fujirebio Diagnostics, Fundacion Progreso y Salud, Galapagos, GammaDelta Therapeutics, GC Biopharma, GC LabCell, GE Healthcare, GEMoaB, GEn1E Lifesciences, GenEdit, Genentech, GeneQuantum Healthcare, Generation Bio, Genethon, Genfit, Genmab, Genomic Testing Cooperative, Genovis, GenScript Biotech, GentiBio, Georgetown University, George Washington University, Georgiamune, GeoVax, Gilead Sciences, Ginkgo BioWorks, Glenmark Pharmaceuticals, GlycoT Therapeutics, Gossamer Bio, Gradalis, Graphite Bio, Graviton Bioscience, Great Ormond Street Hospital (GOSH), Gritstone Bio, Grunenthal, GSK, GT Biopharma, Guardant Health, HalioDx, Halozyme Therapeutics, Hamilton Company, HanAll Pharmaceuticals, HanchorBio, Hangzhou Highlightll Pharmaceutical, Hangzhou Zhongmei Huadong Pharmaceutical, Hanmi Pharmaceutical, Hannover Medical School, Hansa Biopharma, Harbour Biomed, Harvard University, Hebrew University of Jerusalem, Henlius Biotech, HIBio, HiFiBio, Hikma Pharmaceuticals, HitGen, Hoffmann La Roche, Hookipa Pharma, Horizon Pharma plc, Horizon Therapeutics, Hospira, Hospital for Sick Children, Hospital for Special Surgery, Hoth Therapeutics, HotSpot Therapeutics, Huadong Medicine, Hualan Genetic, Humanigen, Hutchmed, Hybridize Therapeutics, I-mab, IASO Biotherapeutics, Icahn School of Medicine at Mount Sinai, IcanoMAB, Ichnos Sciences, ICM, Idorsia, IFM Therapeutics, IGM Biosciences, Ildong Pharmaceutical, ILTOO Pharma, ImaginAb, Imbrium Therapeutics, ImCheck Therapeutics, Imcyse, IMIDomics, Immatics Biotechnologies, Immetas Therapeutics, ImmPACT Bio, Immugenyx, ImmunArray, ImmuneID, Immune Pharmaceuticals, ImmuNext, Immunic, ImmunoChina Pharmaceuticals, ImmunoFlex, Immunomic Therapeutics, Immunovia, Immunscape, Immutep, Imperial College London, In4Derm, INBRAIN Neuroelectronics, IncellDx, Incyte, InDex Pharmaceuticals, Infinity Pharmaceuticals, InflamaCORE, INGENIA Therapeutics, Inimmune, Inmagene Biopharmaceuticals, Innate Pharma, InnDura Therapeutics, INNERVIA Bioelectronics, Innovate UK, Innovative Targeting Solutions, Innovent Biologics, Inotrem, Inovalon, Inserm Transfert, Inspirotec, Institut Curie, Institute for Basic Science, Institute for Bioscience and Biotechnology Research, Institute of Child Health, Institute of Human Virology, Institut Pasteur, Intarcia Therapeutics, Intas Pharmaceuticals, Integral Molecular, Integrated Biosciences, Integrated BioTherapeutics, Intellia Therapeutics, Intellikine, Intrexon, Intrommune Therapeutics, InveniAI, Invitae, iOncologi, Ionis Pharmaceuticals, IONTAS, IQVIA, iReceptor Plus, Ironwood Pharmaceuticals, ISD Immunotech, IsoPlexis, Israeli National Authority for Technological Innovation, iTeos Therapeutics, Jacobio Pharmaceuticals, JAMP Pharma Group, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Janssen Therapeutics, Japan Tobacco, Jasper Therapeutics, Jazz Pharmaceuticals, JDP Therapeutics, Jeffrey Modell Foundation, Jiangsu Chia Tai Tianqing Pharmaceutical, Jiangsu Hansoh Pharmaceutical, Jiangsu Hengrui Medicine, Jiangsu QYuns Therapeutics, Jnana Therapeutics, Johns Hopkins University, Jubilant Therapeutics, JW Therapeutics, Kadmon Pharmaceuticals, Kaken Pharmaceutical, Kalbe Genexine Biologics, Kaleido Biosciences, Kamada, Karolinska Institute, KBI BioPharma, KBP BioSciences, KeifeRx, Kelonia Therapeutics, Kezar Life Sciences, Kineta, King's College Hospital, Kings College London, Kiniksa Pharmaceuticals, Kissei Pharmaceutical, Kite Pharma, Klaria, Knight Therapeutics, Kobe University, KYE Pharmaceuticals, Kymab, Kymera Therapeutics, Kyverna Therapeutics, LabGenius, La Jolla Institute for Allergy & Immunology, Landmark Bio, Laurel Venture Capital, Lead Pharma, LegoChem Biosciences, Leiden University, Leidos, LEO Pharma, Les Laboratoires Servier, Leukemia & Lymphoma Society, LG Life Sciences, LifeMax Laboratories, Ligand Pharmaceuticals, Lipum, LNC, LogicBio Therapeutics, Lonza, Lorna Linda University, LTL Pharma, Lubeck Institute of Experimental Dermatology, Luminary Therapeutics, Luminex, Lumiphore, Lundbeck, Lupin, Lupus Canada, Lupus Foundation of America (LFA), Lupus Research Alliance, Lupus Therapeutics, Lurie Children's Hospital of Chicago, Luye Pharma Group, Lynk Pharmaceuticals, MaaT Pharma, MAB Discovery, mAbXience, Magenta Therapeutics, Magnetic Insight, Mallinckrodt Pharmaceuticals, Marinomed Biotechnologie, Maruho, Massachusetts General Hospital, Massachusetts Institute of Technology, Mass General Brigham, Max Biopharma, Maxcyte, Maxion Therapeutics, Mayo Clinic, MC2 Therapeutics, McGill University, MD Anderson Cancer Center, MD Biosciences, Medac, Medical University of Vienna, Medical University South Carolina, Medidata Solutions, MediGene, Medison Pharma, Medsenic, Meiji Seika, Merck and Co, Merck KGaA, Merus, Mestag Therapeutics, Metaba, Metabolon, Metrion Biosciences, Microba Life Sciences, Microbio Shanghai, Microdrop, Microsoft, MIGAL Galilee Research Institute, Mimetas, MiNK Therapeutics, MIODx, Mitra Biotech, Mitsubishi Tanabe Pharma, Moderna, ModiQuest Research, Monash University, MoonLake Immunotherapeutics, MorphoSys, Mor Research Applications, Mount Sinai Health System, Mount Sinai Medical Center, Mundipharma, Mustang Bio, Mylan Pharmaceuticals, Nanjing Leads Biolabs, NanoView Biosciences, Napo Pharmaceuticals, NASA, National Cancer Institute, National Heart, Lung and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke, National Institutes of Health, National Organization for Rare Disorders, National Research Council Canada, National Science Foundation, National University of Singapore, Nature Technology, Nektar Therapeutics, Nemysis, Neovacs, Neovii Pharmaceuticals, NeoX Biotech, Neptune Technologies & Bioressources, Nestle Health Science, NeuCen BioMed, Neukio Biotherapeutics, NeuroCycle Therapeutics, Newsoara Biopharma, New Wave Ventures, Neximmune, NextCure, Next Generation Manufacturing Canada, Nichi-Iko Pharmaceutical Co, Nimbus Therapeutics, NIMML Institute, NImmune Biopharma, Ningbo Tai Kang Medical Technology, NJCTTQ, Nkarta Therapeutics, NLC Pharma, Noga Therapeutics, Nona Biosciences, Normunity, North Carolina State University, Northern RNA, Northwestern University, Novartis, Novelty Nobility, NovImmune, Novo Nordisk, NTC, Nuance Pharma, Numab, NYU Langone Medical Center, Oak Hill Bio, Oblique Therapeutics, Octagon Research Solutions, Oklahoma Medical Research Foundation, Omega Therapeutics, Omeros, OmniaBio, Oncocross, OncoImmune, Onegevity, Oneness Biotech, oNKo-innate, Ono Pharmaceutical, Optimeos Life Sciences, Orange Grove Bio, Orchard Therapeutics, Orebro University, Osaka University, OSE Immunotherapeutics, Oslo University Hospital, Ospedale San Raffaele, Ossium Health, Otsuka, Outpace Bio, Ovation, Palisade Bio, Pandion Therapeutics, Panorama Research, Pantherna Therapeutics, Parvus Therapeutics, PathAI, Pathios Therapeutics, PatientsLikeMe, Peking University, Penn State College of Medicine, PeptiDream, Peptilogics, Perelman School of Medicine, Pfizer, Phanes Therapeutics, Pharming Group, Pharnext, Phebra, Philogen, Phio Pharmaceuticals, PhoreMost, Pieris Pharmaceuticals, Pinnacle Clinical Research Center, Pionyr Immunotherapeutics, Plan France Relance, Plasticell, Plexision, Pluristem Therapeutics, Pneuma Respiratory, PPD, Precision BioSciences, Precision for Medicine, Precision NanoSystems, PredictImmune, PreventionGenetics, Principia Biopharma, Priovant Therapeutics, ProBioGen, ProciseDx, Progentec Diagnostics, Prokarium, Prometheus Biosciences, Prometheus Laboratories, Protagen, Proteona, ProThera, ProtoKinetix, Provention Bio, Pulmatrix, Purdue Pharma, Pure Biologics, PureTech Health, Pyramid Biosciences, Q32 Bio, Quartet Medicine, Qu Biologics, Queensland Institute of Medical Research (QIMR), Queensland University of Technology, Quell Therapeutics, Quest Diagnostics, Quibim, Quinta-Analytica, Quoin Pharmaceuticals, Quotient, R-Pharm, Ra Pharmaceuticals, Ratio Therapeutics, ReAlta Life Sciences, Recipharm, Recludix Pharma, Recordati, RedHill Biopharma, Regeneron Genetics Center, Regeneron Pharmaceuticals, Regranion, Remix Therapeutics, Repertoire Genesis, Repurpose.AI, Research Foundation to Cure AIDS, RespiVert, ReveraGen BioPharma, Revive Therapeutics, Revolo Biotherapeutics, Rheos Medicines, Ribon Therapeutics, Richard King Mellon Foundation, Rigel Pharmaceuticals, RIKEN Research Institute, RMX Biopharma, Roche, Roivant Sciences, Roswell Biotechnologies, Ryvu Therapeutics, SAB Biotherapeutics, Salix Pharmaceuticals, Samsung Bioepis, Sanford Burnham Institute, Sanofi, Santhera Pharmaceuticals, Sartorius Stedim Biotech, SATT Lutech, Scailyte, Schreiner Group, Schrodinger, SciCann Therapeutics, Scienion, Scleroderma Research Foundation, Scripps Research Institute, Seagen, Seattle Children's Hospital, Seattle Childrens Research Institute, Seattle Genetics, Second Genome, SecondWave Systems, Sedec Therapeutics, Sekris Biomedical, Selecta Biosciences, Selecxine, Selexis, Sementis, Sengenics, Senti Biosciences, SenzaGen, Seqirus, SeraNovo, Seres Therapeutics, Shandong Fontacea Pharmaceutical, Shanghai Model Organisms Center, Shattuck Labs, Shire Laboratories, Silence Therapeutics, Simcere Pharmaceuticals, Similis Bio, Siolta Therapeutics, Sirona Dx, Sitryx, Skyhawk Therapeutics, Solarea Bio, SomaLogic, Sonnet BioTherapeutics, Sonoma BioTherapeutics, Sosei, Sosei Heptares, Spring Bank Pharmaceuticals, SQI Diagnostics, SQZ Biotech, St. Jude Children's Research Hospital, STADA Arzneimittel, Stallargenes, Stallergenes Greer, Stanford University, Stanford University School of Medicine, Stony Brook University, Sutro Biopharma, Suzhou Porton Advanced Solutions, Swedish Orphan Biovitrum, Swixx Biopharma, Sygnature Discovery, Symbiotix Biotherapies, Symphogen, Synaffix, Syndax Pharmaceuticals, Synedgen, Synthekine, Synthorx, Sysmex, T-Cell Protect Hellas, TaiMed, Takeda Pharmaceutical, Takeda Ventures, Tango Therapeutics, Tavotek Biotherapeutics, Tavros Therapeutics, Teijin, Tel Aviv Sourasky Medical Center, Telix Pharmaceuticals, TeneoBio, Tentarix Biotherapeutics, Terumo Blood and Cell Technologies, Tessa Therapeutics, Tetra Bio-Pharma, Tetragenetics, Teva Pharmaceutical Industries, TG Therapeutics, The Parker Institute For Cancer Immunotherapy, Theradiag, Therapix Bio, Theravance Biopharma, Thermo Fisher Scientific, Thomas Jefferson University, Thorne Research, Thunderbolt Pharma, Tikomed, Tiziana Life Sciences, Tizona Therapeutics, Tmunity Therapeutics, TNAX Biopharma, Todos Medical, TONIX Pharmaceuticals, Topas Therapeutics, Tow Foundation, Traaser, Transgene, Transimmune, TransThera, Trethera, TRexBio, TrialSpark, Trillium Therapeutics, Triumvira Immunologics, True Diagnostics, True North Therapeutics, Truveta, Tsinghua University, Turgut Ilaclari, Twist Bioscience, TxCell, UCB, Unilife, Universite Laval, University Health Network, University of Amsterdam, University of Barcelona, University of Birmingham, University of British Columbia, University of Calgary, University of California, San Diego, University of California Berkeley, University of California Los Angeles, University of California San Francisco, University of Cambridge, University of Chicago, University of Cincinnati, University of Connecticut, University of Dundee, University of Edinburgh, University of Erlangen, University of Florida, University of Georgia, University of Houston, University of Kiel, University of Lethbridge, University of Maryland Baltimore, University of Massachusetts Medical School, University of Michigan, University of Minnesota, University of Natural Resources and Life Sciences, University of New South Wales, University of North Texas Health Science Center, University of Pennsylvania, University of Pittsburgh, University of Sheffield, University of Texas Southwestern Medical Center, University of Toronto, University of Utah, University of Verona, University of Virginia, University of Western Ontario, University of West Indies, University of Wisconsin-Madison, University of Zurich, Uppsalagruppen Medical, ValenzaBio, Valneva, Vanderbilt University, Variant Pharmaceuticals, Vedanta Biosciences, Velocity Pharmaceutical Development, Verily, Veritas, Vetter, ViaMune, Viatris, Viela Bio, Vifor-Fresenius Medical Care Renal Pharma, Vinnova, Viome, Vipergen, Vitaeris, Vitalli Bio, Vital Therapies, Vittoria Biotherapeutics, Vium, Vividion Therapeutics, Vivoryon Therapeutics, Vivtex, Voluntis, Voronoi, vTv Therapeutics, Vycellix, VYNE Therapeutics, Watson Laboratories, Weill Cornell Medical College, Wellcome Trust Sanger Institute, WellGen, Whitehead Institute, Willow Biosciences, Windgap Medical, Wisconsin Alumni Research Foundation, Worldwide Clinical Trials, Wuhan Kindstar Diagnostics, WuXi Biologics, WuXi NextCODE Genomics, Wyss Institute, X-chem, X4 Pharmaceuticals, Xencor, Xilio Therapeutics, XL-Protein, Xoma, XtalPi, Xyphos Biosciences, Y-Biologics, Yale University, Yangtze River Pharmaceutical Group, Yeda Research and Development Company, Yisheng Biopharma, ZAI Laboratory, Zealand Pharma, Zebra Biologics, Zenas BioPharma, Zenyaku Kogyo, Zura Bio, Zylo Therapeutics, Zymeworks, ZyVersa Therapeutics

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.